Search results
1 company and 4 research reports found for "Clavis Pharma"
Company results
- Clavis Pharma
Clavis has two Phase III cancer therapies. CP-4126 (improved gemcitabine) targets pancreatic cancer;...
Sector reports
No sector reports have been found.
Research results
Clavis Pharma
Resistance is useless
Outlook | Pharmaceutical & Healthcare | 28/02/2012Clavis Pharma develops cancer therapies with improved delivery characteristics that also overcome low hENT1, a widespread drug resistance mechanism to...
Clavis Pharma
Morbid probabilities
QuickView | Pharmaceutical & Healthcare | 25/10/2011A trial to evaluate hENT1 levels in a sample of 500 pancreatic cancer patients has reported initial data showing around two thirds of patients have lo...
Clavis Pharma
Portfolio update
QuickView | Pharmaceutical & Healthcare | 06/05/2011The 5 May Q1 results focused on a new clinical candidate, CP-4200 for Mylodysplasia Syndrome (MDS), the precursor to Acute Myeloid Leukaemia (AML). Th...
Clavis Pharma
A hENT of success
QuickView | Pharmaceutical & Healthcare | 15/11/2010The 11 November Asian deal with Clovis (a well-funded US private pharma co) builds on the November 2009 Americas and EU deal. These now total $585m (w...
